Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer | Zendy

Johannes Ettl | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer

Author(s) -

Johannes Ettl

Publication year - 2016

Publication title -

breast care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.767

H-Index - 30

eISSN - 1661-3805

pISSN - 1661-3791

DOI - 10.1159/000447417

Subject(s) - palbociclib , medicine , cyclin dependent kinase , breast cancer , clinical trial , oncology , clinical practice , cyclin dependent kinase 4 , cancer , clinical significance , metastatic breast cancer , cell cycle , family medicine , cyclin dependent kinase 2

Palbociclib is the first inhibitor of the cyclin-dependent kinases (CDK) 4 and 6 to be introduced into clinical practice. Preclinical investigations led to its clinical development in advanced hormone receptor (HR)-positive breast cancer. To date, 2 significant clinical trials have been fully published. In this article, the results of these trials and their clinical relevance for the management of HR-positive advanced breast cancer are discussed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research